Use of the protease inhibitor saquinavir hard gel in human immunodeficiency virus-infected patients in the early period of highly active antiretroviral therapy: Does it affect long-term treatment outcome?

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 10, 2003, Pages 743-749

  Jensen Fangel, Søren ^a   Pedersen, Court ^b   Nielsen, Henrik ^c   Tauris, Palle ^d   Møller, Axel ^e   Søorensen, Henrik Toft ^a   Obel, Niels ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d HERNING HOSPITAL   (Denmark)

^e KOLDING HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENMARK; DRUG CAPSULE; DRUG EXPOSURE; DRUG POTENCY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; POPULATION RESEARCH; PROBABILITY; RISK ASSESSMENT; TIME; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAPSULES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DENMARK; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; ODDS RATIO; SAQUINAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0242288458     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540310016187     Document Type: Article

References (25)

1. Gulick RM, Mellors JW, Havlir D, Eton JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9.
2. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334: 1011-7.
3. Kirk O, Mocroft A, Pradier C, Bruun JN, Hemmer R, Clotet B, et al. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. AIDS 2001; 15: 999-1008.
4. Jensen-Fangel S, Kirk O, Larsen L, Blaxhult A, Gerstoft J, Pedersen C, et al. Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study. Scand J Infect Dis 1999; 31: 489-93.
5. d'Arminio MA, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998; 12: 1631-7.
6. Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14: 141-9.
7. Jensen-Fangel S, Pedersen C, Larsen CS, Tauris P, Moller A, Obel N. Changing demographics in an HIV-infected population: results from an observational cohort study in western Denmark. Scand J Infect Dis 2001; 33: 765-70.
8. 3 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
9. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13: F35-43.
10. Casado JL, Perez-Elias MJ, Antela A, Sabido R, Marti-Belda P, Dronda F, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998; 12: F131-5.
11. Fatkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11: F113-6.
12. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160: 1123-32.
13. Jensen-Fangel S, Kirk O, Blaxhult A, Gerstoft J, Pedersen C, Black FT, et al. The insufficient suppression of viral load by saquinavir hard get is reversible: a retrospective cohort study. HIV Clin Trials 2001; 2: 122-7.
14. Jensen-Fangel S, Thomsen HF, Larsen L, Black FT, Obel N. The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. J Acquir Immune Defic Syndr 2001; 27: 124-9.
15. Albrecht MA, Bosch RJ, Hammer SM, Lion SH, Kessler H, Para MF, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001; 345: 398-407.
16. Salzberger B, Rockstroh J, Wieland U, Franzen C, Schwenk A, Jutte A, et al. Clinical efficacy of protease inhibitor based antiretroviral combination therapy - a prospective cohort study. Eur J Med Res 1999; 4: 449-55.
17. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study Lancet 1998; 351: 723-4.
18. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183: 1328-35.
19. Schapiro JM, Winters MA, Lawrence J, Merigan TC. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS 1999; 13: 359-65.
20. Dronda F, Casado JL, Moreno S, Hertogs K, Garcia-Arata I, Antela A, et al. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Res Hum Retroviruses 2001; 17: 211-5.
21. Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, et al. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. J Infect Dis 1999; 179: 1356-64.
22. Merry C, Barry MG, Mulcahy F, Halifax KL, Back DJ. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997; 11: F117-20.
23. Kirk O, Katzenstein TL, Gerstoft J, Mathiesen L, Nielsen H, Pedersen C, Lundgren JD. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999; 13: F9-F16.
24. Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team. AIDS 1998; 12: F103-9.
25. Cohen Stuart JW, Schuurman R, Burger DM, Koopmans PP, Sprenger HG, Juttmann JR, et al. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). AIDS 1999; 13: F53-8.